SEMA4D and early-onset autosomal dominant Alzheimer disease: An anti-Sema3A antibody has been patented to reduce immunosuppression caused by tumor-secreted Sema3A, and is available to the treatment of Alzheimer disease and immune dysfunction; Sema4D inhibitors are also patented to increase the frequency of tumor-infiltrating leukocytes by blocking the combination of Sema4D with its receptor (49), and is suitable for the treatment of human head and neck cancer, colon cancer, breast cancer, etc (50).